A Phase Ib Study of Simmitecan (LP) Single-Agent and in Combination with 5-Fluorouracil/leucovorin (5-FU/LV) or Thalidomide (T) in Patients with Advanced Solid Tumor.

Jifang Gong,Ting Deng,Jie Li,Ming Lu,Jian Li,Yi Ba,Qiuqiong Yu,Lin Shen
DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.3523
IF: 45.3
2020-01-01
Journal of Clinical Oncology
Abstract:3523 Background: Simmitecan (LP), a novel 9-substituted lipophilic camptothecin derivative, is a potent inhibitor of topoisomerase I with anti-tumor activity single agent or in combination with other anti-tumor agents, i.e. thalidomide or anti-PD-1 antibody in xenograft models. In this phase Ib study (NCT02870036), we evaluate the safety and anti-tumor effects of LP as monotherapy or in combination therapies in patients (pts) with advanced solid tumors. Methods: This open-label, multi-cohort phase Ib study was conducted at 3 academic centers in China. Eligible pts had advanced cancer without standard treatment options. Prior irinotecan treated failure pts was eligible. In the single agent study, enrolled pts was allocated to received intravenous(iv) 50, 80, or 120 mg/m2 of LP Q2W to determine the safety of LP. After single agent study finished, enrolled pts allocated in LP+5-FU/LV cohorts received 50, 65, or 80 mg/m2 of LP then LV 400 mg/m2 and 5-FU bolus at 400 mg/m2 followed by 5-FU continuous iv of 2400 mg/m2 Q2W; pts in LP+T cohorts received LP 65 mg/m2 Q2W + thalidomide 50mg QD or thalidomide 100mg QD, or LP 80 mg/m2 Q2W + thalidomide 50mg QD. Treatment repeated in 28-day cycles until disease progression or unacceptable toxicity. Results: Between October 2016 to February 2019, 41 pts, median age of 55.1 (range 29-69) years, were enrolled, 13 in LP monotherapy, 10 in LP + 5-FU/LV and 18 in LP + T. Over all, no dose limited toxicity (DLT) occurred. The most common (≥20%) grade 3/4 AE among three regimens was neutropenia (44%, 70% and 89% respectively in LP, LP+5FU/LV and LP+T),and treatment related SAEs were similar, i.e. anemia and febrile neutropenia (11.1% each) in LP, diarrhea (10%) in LP+5-FU/LV, febrile neutropenia (5.6%) in LP+T. Majority of enrolled pts (24/41, 59%) had progressed on prior irinotecan, nevertheless, partial response (PR) was observed in 1 colorectal cancer pt treated with LP 80 mg/m2 + thalidomide 50mg. Disease control rate (DCR, SD≥12 weeks or CR or PR) were 60%, 80% and 61% and median progress free survival were 2.71, 4.17 and 2.76 months respectively in LP, LP + 5-FU/LV and LP+T cohorts. Conclusions: This study showed the safety profiles are manageable, either LP monotherapy or combination therapies, no DLT or safety concern was elicited in combination compared to single agent, and the LP + 5-FU/LV regimen showed higher DCR. A phase II study in pts with metastatic NEC is on-going to explore safety and efficacy of LP + 5-FU/LV regimen combined with toripalimab, an anti-PD-1 antibody. Clinical trial information: 02870036 .
What problem does this paper attempt to address?